Brayer, J., & Baz, R. (2017). The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol.
Chicago-stil citatBrayer, Jason, och Rachid Baz. "The Potential of Ixazomib, a Second-generation Proteasome Inhibitor, in the Treatment of Multiple Myeloma." Ther Adv Hematol 2017.
MLA-referensBrayer, Jason, och Rachid Baz. "The Potential of Ixazomib, a Second-generation Proteasome Inhibitor, in the Treatment of Multiple Myeloma." Ther Adv Hematol 2017.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.